CHRS
Income statement / Annual
Last year (2023), Coherus BioSciences, Inc.'s total revenue was $257.24 M,
an increase of 21.89% from the previous year.
In 2023, Coherus BioSciences, Inc.'s net income was -$237.89 M.
See Coherus BioSciences, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$257.24 M
|
$211.04 M
|
$326.55 M
|
$475.82 M
|
$356.07 M
|
$1.56 M
|
$1.56 M
|
$190.11 M
|
$30.04 M
|
$31.11 M
|
| Cost of Revenue |
$162.78 M |
$70.08 M |
$57.59 M |
$37.67 M |
$17.08 M |
$3.24 M |
$160.53 M |
$254.44 M |
$212.68 M |
$78.22 M |
| Gross Profit |
$94.46 M |
$140.96 M |
$268.96 M |
$438.16 M |
$338.99 M |
-$1.68 M |
-$158.98 M |
-$64.33 M |
-$182.64 M |
-$47.12 M |
| Gross Profit Ratio |
0.37 |
0.67 |
0.82 |
0.92 |
0.95 |
-1.08 |
-102.17 |
-0.34 |
-6.08 |
-1.51 |
| Research and Development
Expenses |
$109.44 M
|
$199.36 M
|
$363.11 M
|
$142.76 M
|
$94.19 M
|
$110.24 M
|
$162.39 M
|
$254.44 M
|
$213.06 M
|
$78.22 M
|
| General & Administrative
Expenses |
$0.00
|
$187.98 M
|
$161.01 M
|
$135.28 M
|
$132.54 M
|
$94.18 M
|
$71.30 M
|
$51.60 M
|
$36.05 M
|
$17.56 M
|
| Selling & Marketing
Expenses |
$0.00
|
$10.50 M
|
$8.70 M
|
$3.80 M
|
$4.50 M
|
$2.80 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$185.62 M
|
$198.48 M
|
$169.71 M
|
$139.08 M
|
$137.04 M
|
$94.18 M
|
$71.30 M
|
$51.60 M
|
$36.05 M
|
$17.56 M
|
| Other Expenses |
$0.00 |
$3.82 M |
-$283,000.00 |
$554,000.00 |
$2.61 M |
$4.69 M |
$3.40 M |
-$3.88 M |
-$4.84 M |
-$18.60 M |
| Operating Expenses |
$301.45 M |
$397.84 M |
$532.82 M |
$281.84 M |
$231.23 M |
$204.42 M |
$233.69 M |
$306.04 M |
$249.11 M |
$95.79 M |
| Cost And Expenses |
$460.44 M |
$467.92 M |
$590.41 M |
$319.51 M |
$248.30 M |
$204.42 M |
$233.69 M |
$306.04 M |
$249.11 M |
$95.79 M |
| Interest Income |
$0.00 |
$30.57 M |
$21.56 M |
$20.57 M |
$16.00 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$40.54 M |
$32.47 M |
$22.96 M |
$21.17 M |
$17.60 M |
$9.68 M |
$9.55 M |
$7.98 M |
$33,000.00 |
$3.90 M |
| Depreciation &
Amortization |
$3.79 M
|
$3.70 M
|
$5.66 M
|
$4.97 M
|
$3.26 M
|
$3.24 M
|
$3.40 M
|
$3.00 M
|
$1.87 M
|
$674,000.00
|
| EBITDA |
-$193.94 M
|
-$255.58 M
|
-$260.69 M
|
$161.84 M
|
$111.03 M
|
-$204.42 M
|
-$225.34 M
|
-$116.81 M
|
-$222.04 M
|
-$82.72 M
|
| EBITDA Ratio |
-0.75 |
-1.2 |
-0.81 |
0.33 |
0.31 |
-128.36 |
-147 |
-0.63 |
-7.45 |
-2.68 |
| Operating Income Ratio
|
-0.79
|
-1.22
|
-0.81
|
0.33
|
0.3
|
-131.37
|
-149.19
|
-0.61
|
-7.29
|
-2.08
|
| Total Other
Income/Expenses Net |
-$35.07 M
|
-$34.87 M
|
-$23.24 M
|
-$20.61 M
|
-$14.99 M
|
-$4.99 M
|
-$6.15 M
|
-$11.86 M
|
-$4.87 M
|
-$22.50 M
|
| Income Before Tax |
-$238.27 M |
-$291.75 M |
-$287.10 M |
$135.71 M |
$92.78 M |
-$209.41 M |
-$238.29 M |
-$127.79 M |
-$223.94 M |
-$87.18 M |
| Income Before Tax Ratio
|
-0.93
|
-1.38
|
-0.88
|
0.29
|
0.26
|
-134.58
|
-153.14
|
-0.67
|
-7.45
|
-2.8
|
| Income Tax Expense |
-$380,000.00 |
$34.87 M |
$19.22 M |
$3.46 M |
$2.94 M |
$4.69 M |
$9.44 M |
$656,000.00 |
-$7.35 M |
-$15.41 M |
| Net Income |
-$237.89 M |
-$326.63 M |
-$306.32 M |
$132.24 M |
$89.83 M |
-$209.34 M |
-$238.17 M |
-$127.34 M |
-$223.26 M |
-$87.13 M |
| Net Income Ratio |
-0.92 |
-1.55 |
-0.94 |
0.28 |
0.25 |
-134.54 |
-153.07 |
-0.67 |
-7.43 |
-2.8 |
| EPS |
-2.53 |
-4.21 |
-4.06 |
1.85 |
1.29 |
-3.22 |
-4.48 |
-3.04 |
-6.01 |
-10.64 |
| EPS Diluted |
-2.53 |
-4.21 |
-4.06 |
1.62 |
1.23 |
-3.22 |
-4.48 |
-3.04 |
-6.01 |
-10.64 |
| Weighted Average Shares
Out |
$94.16 M
|
$77.63 M
|
$75.45 M
|
$71.41 M
|
$69.68 M
|
$65.01 M
|
$53.13 M
|
$41.91 M
|
$37.12 M
|
$8.19 M
|
| Weighted Average Shares
Out Diluted |
$94.16 M
|
$77.63 M
|
$75.45 M
|
$83.49 M
|
$73.19 M
|
$65.03 M
|
$53.13 M
|
$41.91 M
|
$37.12 M
|
$8.19 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
